![]() ![]() By March 19, Israeli’s Ministry of Justice announced that a generic version of AbbVie’s HIV treatment Kaletra has been approved for importation into that country despite the fact that AbbVie’s patent protection for Kaletra in Israel doesn’t expire until 2024. While some firms have been filing for patents to protect their coronavirus treatment innovations, others have faced ultimatums by government to hand over their IP rights during this time of global crisis. It also reduces the risk of the development of cytokine storms, a form of autoimmune disorder involving activated white blood cells which can cause respiratory inflammation when COVID-19 enters the lungs. The treatment leverages Premier Biomedical’s previous technological developments designed to remove blood-borne antigens from patients. The method involves the use of antibodies targeting COVID-19 replication pathways, allowing the coronavirus to be removed through an extracorporeal blood treatment performed at a clinic. On March 23, Jackson Center, PA-based Premier Biomedical announced that it would have exclusive rights to practice a method of treating COVID-19 infection being patented by a company executive. WP1122 disrupts the metabolism of glucose which, along with depriving cancer cells of energy, could also do the same for cells hosting COVID-19 and possibly improve immune system response. WP1122 is a compound in Moleculin’s cancer drug portfolio developed to target highly glycolytic tumors which are difficult to treat, including brain tumors and pancreatic cancer. On March 20, Houston, Texas-based Moleculin Biotech issued a press release about a patent application covering the use of the inhibitor compound WP1122 to limit coronavirus replication in patients. companies had announced that their COVID-19 research had led to the filing of patent applications covering methods of treating patients infected with the coronavirus. A recent New York Times article discusses a number of such efforts, mainly those involving government-backed research in China and European research firms which receive public funding.īy late March, however, a couple of U.S. As COVID-19 has grown into a threat to national security across the world, many countries have stepped up their support of vaccination research programs. On March 20, the World Health Organization (WHO) announced that it would be implementing a global clinical trial of several antivirals, including ones that have been previously used to treat malaria and HIV. No cures or treatments for COVID-19 currently exist, forcing much of the developed world to adjust to the new normal of socializing via webcam and spend their weekends watching sports broadcasts from years past. In the United States, the virus seems to be affecting young people quite aggressively as well. About 15 percent of all COVID-19 infections lead to severe symptoms of respiratory disease. Those figures have been increasing exponentially each day.Īccording to the statistics we have from China and Italy, the vast majority of people who contract COVID-19 exhibit flu-like symptoms, the virus has proven to be most dangerous to adults aged 60 or older, as well as individuals with underlying health conditions. As of the afternoon of March 27, the Coronavirus Resource Center at Johns Hopkins University reports that more than 585,000 cases of COVID-19 infection have been confirmed worldwide, resulting in a total of 26,819 deaths. ![]() In the less than three months since that first death, this new strain of the severe acute respiratory syndrome-related (SARS) coronavirus has shuttered social gatherings, precipitated a mandatory work-from-home revolution and decimated large parts of the world’s economy. Since China announced the first fatality caused by a virus about which little was known at the time, coronavirus and the disease it causes, COVID-19, has grown to pandemic proportions. “The coronavirus situation highlights a unique tension in the patent system, which can at once incentivize and spur research and development activities in response to a health crisis and also draw the ire of public health advocates, who see patents as barriers to better patient health outcomes.”
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |